"The preliminary unaudited rate of adverse-event (AE) related discontinuations in the RESILIENT study was 4.8%," said Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals. "This compares favorably to the blinded AE-related discontinuation rates in our two previous Phase 3 trials: 6.0% in RELIEF which achieved statistical significance on the primary endpoint (p=0.010), and 10.7% in RALLY which was stopped at the interim analysis. We later learned that an unexpectedly high rate of AE-related discontinuations in RALLY contributed to missing the primary endpoint.